A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors
The purpose of this study is to determine the bioequivalence of the new oral capsule formulation to the currently used oral capsule formulation of topotecan.
Checked against the public recordLast updated Nov 14, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- GlaxoSmithKline
- Interventions being studied
- Drug: topotecan
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subjects with advanced solid tumors. * At least 4 weeks since last chemotherapy, radiotherapy, biologic therapy or surgery. * Subjects must be free of post-treatment side effects. Exclusion Criteria: * Women who are pregnant or lactating * Subjects with uncontrolled emesis, regardless of etiology, active infection.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- GSK Investigational SiteLebanon, New Hampshire
- GSK Investigational SiteThe Bronx, New York
- GSK Investigational SitePhiladelphia, Pennsylvania
- GSK Investigational SiteNashville, Tennessee
- GSK Investigational SiteSan Antonio, Texas
- GSK Investigational SiteMorgantown, West Virginia
- GSK Investigational SiteAmsterdam
- GSK Investigational SiteUtrecht
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 14, 2017. Always confirm current availability with the study team.